Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons
Aug 2026· Neurological Sciences· Vol 47· 0 citations· 49 references
Medicine
TL;DR
The p-tau217/Aβ42 ratio approximately doubled the diagnostic odds ratio compared with p-tau217 alone and its application in clinical practice is supported by the fact that the p-tau217/Aβ42 ratio performed much better than p-tau217 alone.
Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms, but it should not be interpreted as a stand-alone test.
Oliwia Lenkiewicz, Julia Lenkiewicz, Z. Chmielewska et al.· International Journal of Inn...· 0 citations
The plasma p-tau217/Aβ42 ratio functions as an effective first-line screening tool that resolves ambiguous cases, significantly decreases gray-zone classifications, and increases diagnostic confidence, but does not significantly enhance absolute diagnostic discrimination (AUC) relative to p-tau217 alone.
Adil Khan, Awais Ahmad, Usman Khan et al.· Journal of Saidu Medical Col...· 0 citations
Findings support the Access p-Tau217 (RUO) assay as a robust, high-throughput assay for plasma biomarker-based discrimination of PET-defined amyloid pathology in AD applications.
P. Wynveen, A. Becker, S. Levin et al.· medRxiv· 0 citations
OBJECTIVE
Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely underst...
Mingxing Jiang, Guo-Yu Lan, Jiayi Zhu et al.· Annals of Neurology· 0 citations
Blood-based biomarkers could broaden access to Alzheimer’s disease diagnostics, but their ability to approximate tau PET, and to address gray-zone results, remains uncertain. We evaluated plasma p-tau217 against tau PET using a harmonized ADNI baseline cohort and an independently derived temporal meta-ROI tau-PET thres...
